# K141274: Quanta Flash ¿2GP1-DOMAIN1; Controls, Hemosil Acustar Anti-¿2GPI DOMAIN1; Controls.

- Pathway: 510(k) (Traditional)
- Applicant: Inova Diagnostics, Inc.
- Decided: Feb 13, 2015 after 273 days
- Product code: MSV (System,Test,Antibodies,B2 - Glycoprotein I (B2 - Gpi))
- Device class: 2
- Regulation: 21 CFR 866.5660
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 1 generation back to K970551 (1997). 1 ancestor in all.
No later device cites it as a predicate yet.
0 of 2 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K970551: Quanta Lite B2GPI Igg, Inova Diagnostics, Inc. (1997) Summary page 4.

## Indications for use
The QUANTA Flash® B2GP1-Domain1 is an in vitro chemiluminescent immunoassay (CIA) for the semi-quantitative determination of IgG autoantibodies to B2GP1-Domain1 in human serum. The presence of anti-B2GP1-Domain1 autoantibodies is used in conjunction with clinical and other laboratory findings as an aid in the diagnosis of antiphospholipid syndrome. The QUANTA Flash® B2GP1-Domain1 is not intended to replace assays for antibodies against the whole B2GP1 molecule. Testing for antibodies to the whole B2GP1 molecule is required according to the classification criteria for antiphospholipid syndrome. The QUANTA Flash B2GP1-Domain1 Controls are intended for quality control purposes of the QUANTA Flash B2GP1-Domain1 chemiluminescent immunoassay (CIA) kit. The HemosIL® AcuStar Anti-B2GPI Domain 1 is an in vitro chemiluminescent immunoassay (CIA) for the semi-quantitative determination of IgG autoantibodies to B2GPI Domain 1 in human serum. The presence of anti-B2GPI Domain 1 autoantibodies is used in conjunction with clinical and other laboratory findings as an aid in the diagnosis of antiphospholipid syndrome. The HemosIL® AcuStar Anti-B2GPI Domain 1 is not intended to replace assays for antibodies against the whole B2GPI molecule. Testing for antibodies to the whole B2GPI molecule is required according to the classification criteria for antiphospholipid syndrome. The HemosIL AcuStar Anti-B2GPI Domain 1 Controls are intended for quality control purposes of the HemosIL AcuStar Anti-B2GPI Domain 1 chemiluminescent immunoassay (CIA) kit.

Source page: https://510kreport.com/device/K141274
Methodology: https://510kreport.com/methodology